168 results on '"Claudiani, Simone"'
Search Results
2. Cardiovascular events in CML patients treated with Nilotinib: validation of the HFA-ICOS baseline risk score
3. Long-term outcomes after upfront second-generation tyrosine kinase inhibitors for chronic myeloid leukemia: managing intolerance and resistance
4. FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertions
5. The outcome of post-transplant asciminib in patients with chronic myeloid leukaemia
6. Exploring alternative cellular targets amenable to combination therapy in myelofibrosis
7. COVID-19 vaccine boosted immunity against Omicron in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors
8. Third primary SARS-CoV-2 mRNA vaccines enhance antibody responses in most patients with haematological malignancies
9. Effect of tyrosine kinase inhibitors on male fertility in patients with chronic phase chronic myeloid leukemia
10. Impact of BCR::ABL1single nucleotide variants on asciminib efficacy
11. Treatment‐free remission in CML patients with additional chromosome abnormalities in the Philadelphia‐positive clone or variant Philadelphia translocations.
12. Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients
13. COVID-19 vaccine boosted immunity against Omicron in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors
14. Real-World Experience of Asciminib: Factors Associated with Response
15. A retrospective observational research study to describe the real‐world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands
16. Third primary SARS-CoV-2 prophylactic mRNA vaccines enhances antibody responses in the majority of patients with haematological malignancies: Results from the MARCH study
17. Long-term persistence of natural anti-SARS-CoV-2 antibodies and mild impact of SARS-CoV-2 infection in CML patients: results from a seroprevalence study
18. Assessment of quantitative polymerase chain reaction for BCR–ABL1 transcripts in chronic myeloid leukaemia: Are improved outcomes in patients with e14a2 transcripts an artefact of technology?
19. Durable humoral responses after the second anti‐SARS‐CoV‐2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors
20. Is COVID‐19 less severe in CML patients than in those with other haematological cancers?
21. Carfilzomib Enhances the Suppressive Effect of Ruxolitinib in Myelofibrosis
22. Incidence, Interpretation and Management of Liver Function Abnormalities in Patients with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKI)
23. TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia
24. Durable humoral responses after the second anti‐SARS‐CoV‐2 vaccine dose in chronic myeloid leukaemia patients on tyrosine kinase inhibitors.
25. Prevalence of Sars-Cov-2 Infection in Patients with Chronic Myeloid Leukemia
26. Identification of genetic targets in acute myeloid leukaemia for designing targeted therapy
27. Platelet function in patients with chronic myeloid leukemia treated with asciminib
28. The proportion of different BCR-ABL1 transcript types in chronic myeloid leukemia. An international overview
29. Introducing a Predictive Score for Successful Treatment Free Remission in Chronic Myeloid Leukemia (CML)
30. Prolonged treatment-free remission in chronic myeloid leukemia patients with previous BCR-ABL1 kinase domain mutations
31. The influence of salivary amylase on total amylase elevation in CML patients treated with TKI therapy: a case series of 3 patients
32. Blast crisis of chronic myeloid leukemia with plasmacytoid dendritic cell phenotype associated with a rare fusion transcript, e13a3 BCR–ABL1
33. Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors
34. T-cell prolymphocytic leukaemia in a patient with chronic myeloid leukaemia receiving nilotinib: first documented report
35. MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia
36. TKI dose reduction can effectively maintain major molecular remission in patients with chronic myeloid leukaemia.
37. Identification of genetic targets in acute myeloid leukaemia for designing targeted therapy.
38. The argument for using imatinib in CML
39. "Function First" Screen of Primary AML Cells Identifies Common and Personalised Therapeutic Targets
40. 34-Year Single Center Observational Review of Ex-Vivo T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplants for Chronic Myeloid Leukemia
41. Dose Reduction of First and Second Generation TKIs Is Effective in the Maintenance of Major Molecular Response and May Predict Successful Tfr in CML Patients
42. Development of artificial bone marrow fibre scaffolds to study resistance to anti-leukaemia agents
43. The Real World Use of Bosutinib in Patients with Chronic Myeloid Leukaemia
44. Somatic Mutations in Epigenetic Modifiers Identified Using Next Generation Sequencing (NGS) in Diagnostic Samples of CML-CP Can Predict Poor Outcome on Imatinib Which Is Abrogated By Frontline 2G-TKI Therapy
45. Safety and efficacy of bosutinib in fourth-line therapy of chronic myeloid leukemia patients.
46. Cognitive dysfunction after withdrawal of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia
47. Safety and Efficacy of Bosutinib in Fourth Line Therapy of Chronic Myeloid Leukemia Patients
48. The Association of Gilbert's Syndrome with Hyperbilirubinaemia Occurring on Any of Imatinib, Dasatinib and Nilotinib in Patients with Chronic Myeloid Leukaemia (CML)
49. Excellent Outcome and Good Tolerability of Long-Term Imatinib in Patients with Chronic Myeloid Leukemia (CML)
50. A Multi-Institutional Retrospective Analysis of Tyrosine Kinase Inhibitor (TKI) Clinical and Preclinical Efficacy According to BCR-ABL Mutation Status in CP-CML Patients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.